Security
Eikon Therapeutics, Inc. Common Stock · EIKN
EIKNNASDAQCommon stockCurrentCIK 1861123Updated Oct 4, 2026
EIKN price & chart
Loading TradingView…
NASDAQ:EIKN on TradingView ↗About the company
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.
In the news
Eikon Therapeutics to Participate in Investor Conferences in September 2026 ↗
Recent filings
SCHEDULE 13G/A - filed by Abu Dhabi Investment Authority regarding Eikon Therapeutics, Inc.
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G - filed by Innovation Endeavors III LP regarding Eikon Therapeutics, Inc.
SCHEDULE 13G - filed by PERLMUTTER ROGER M regarding Eikon Therapeutics, Inc.
Offerings
Registration 333-292633
- Gross proceeds
- 381196800.0
- Net proceeds
- 354513024.0
- Deal price
- 18.0
- Shares
- 21177600
- Offering price
- $18.00
- Ticker
- EIKN
Registration 333-293213
Filing attachments
eikn-ex99_1.htm · 8-K · 2026-08-14
EX-99.1 2 eikn-ex99_1.htm EX-99.1 Q3 Company Update August 2026 Exhibit 99.1 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation, cost, timing, progress, and results of our preclinical studies and clinical trials for our product candidates; our ab…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 eikn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates • Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005 • Presented data at the American Society for Clinical…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-06-01
EX-99.1 2 eikn-ex99_1.htm EX-99.1 Q2 Company Update June 2026 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation, cost, timing, progress, and results of our preclinical studies and clinical trials for our product candidates; our ability to levera…
Read attachment ↗eikn-ex99_2.htm · 8-K · 2026-06-01
EX-99.2 3 eikn-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology • TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development • Phase 1/2 trial of EIK1003 reports updated safe…
Read attachment ↗eikn-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 eikn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates • Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026 • Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibit…
Read attachment ↗eikn-ex99_2.htm · 8-K · 2026-05-11
EX-99.2 3 eikn-ex99_2.htm EX-99.2 Q2 Company Presentation May 2026 Exhibit 99.2 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation, cost, timing, progress, and results of our preclinical studies and clinical trials for our product candidates; our…
Read attachment ↗